SELECTIVE DEPLETION OF TUMOR-SPECIFIC REGULATORY T CELLS IN COMBINATION WITH LOW DOSE CHEMOTHERAPY WITH OR WITHOUT PD-1 BLOCKADE IMPROVES ANTI-TUMOR T CELL RESPONSES IN SOLID TUMORS

被引：0

作者：

Axe, Dorothee Saddier ^{[1
]}

Kuhne, Michelle ^{[1
]}

Jain, Renu ^{[1
]}

Weist, Brian ^{[1
]}

机构：

[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0807

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

807

引用

页码：A843 / A843

页数：1

共 50 条

[31] Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
Yang, Hua-Yu
Sun, Le-Jia
Mao, Yi-Lei
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2018, 17 (02) : 93 - 94
[32] Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer
Mo, Lijun
Chen, Qianmei
Zhang, Xinji
Shi, Xiaojun
Wei, Lili
Zheng, Dianpeng
Li, Hongwei
Gao, Jimin
Li, Jinlong
Hu, Zhiming
VACCINE, 2017, 35 (43) : 5932 - 5938
[33] Tumor Cell-intrinsic Activation of the Immune Receptor RIG-I in Combination with Immune Checkpoint Blockade improves anti-Tumor T-Cell Responses
Thier, B.
Such, L.
Sucker, A.
Coch, C.
Hartmann, G.
Schadendorf, D.
Griewank, K.
Trilling, M.
Zhao, F.
Paschen, A.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 10 - 10
[34] TUMOR-INFILTRATING REGULATORY T CELLS FAVOR TUMOR DEVELOPMENT BY SUPPRESSING LOCAL TUMOR-SPECIFIC T CELL RESPONSES IN PRIMARY AND METASTATIC LIVER CANCER
Pedroza-Gonzalez, A.
Verhoef, C.
Ijzermans, J. N.
Peppelenbosch, M.
Kwekkeboom, J.
Janssen, H. L.
Sprengers, D.
JOURNAL OF HEPATOLOGY, 2012, 56 : S126 - S126
[35] PD-1 blockade may promote not only the reactivation of preexisting tumor-specific T cell clones but also the infiltration of new clones
Inozume, T.
Nagasaki, J.
Kawazu, M.
Kawamura, T.
Yamashita, K.
Togashi, Y.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S204 - S204
[36] MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Ebert, Peter J. R.
Cheung, Jeanne
Yang, Yagai
McNamara, Erin
Hong, Rebecca
Moskalenko, Marina
Gould, Stephen E.
Maecker, Heather
Irving, Bryan A.
Kim, Jeong M.
Belvin, Marcia
Mellman, Ira
IMMUNITY, 2016, 44 (03) : 609 - 621
[37] Treatment with doxorubicin and PD-1/CTLA-4 blockade improves T cell activation and anti-tumor efficacy in MCA-205 murine fibrosarcoma
Therrien, Nicholas R.
Tellez, Cristiam Morreno
Kemp, Lindsey E.
Powers, Kyle N.
Levey, Daniel
Chand, Dhan
Wilkens, Margaret
Grossman, Joseph
Goodspeed, Andrew
Davila, Eduardo
Wilky, Breelyn A.
JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
[38] Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma
Ligtenberg, Maarten A.
de Coana, Yago Pico
Shmushkovich, Taisia
Yoshimoto, Yuya
Truxova, Iva
Yang, Yuan
Betancur-Boissel, Monica
Eliseev, Alexey V.
Wolfson, Alexey D.
Kiessling, Rolf
MOLECULAR THERAPY, 2018, 26 (06) : 1482 - 1493
[39] Depletion of glioma infiltrating myeloid derived suppressor cells promotes anti-tumor T cell responses
Kamran, Neha
Li, Youping
Moreno-Ayala, Mariela
Assi, Hikmat
Candolfi, Marianela
Dzaman, Marta
Lowenstein, Pedro
Castro, Maria
CANCER RESEARCH, 2015, 75
[40] EVIDENCE FOR DURABLE ANTI-TUMOR RESPONSES BY TAC-T CELLS IN PRECLINICAL MODELS OF SOLID TUMORS
MacGregor, Heather
Moogk, Duane
Xu, Stacey
Hammill, Joanne
Ip, Philbert
Wang, Ling
Shetty, Swati
MacDonald, Kyle
Shaver, Laura
Pirati, Sailaja
Lal, Prabha
Helsen, Christopher
Bramson, Jonathan
Sengupta, Sadhak
Bader, Andreas
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A276 - A276

← 1 2 3 4 5 →